Evidence map›Paper›PMID 36254233›Full record

ArticleOxidative medicine and cellular longevity2022

Identification of ATG7 as a Regulator of Proferroptosis and Oxidative Stress in Osteosarcoma.

Runyi Jiang, Shaohui He, Haiyi Gong, Yao Wang, Wei Wei, Jun Chen, Jinbo Hu, Chen Ye, Shuchen LiuHuang, Saiying Jin and 3 more

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Programmed cell death in triple-negative breast cancer.Cellular & molecular biology letters · 2025
    Review
  2. Article
  3. Selagibenzophenone B and Its Derivatives:ACS bio & med chem Au · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Runyi JiangSpinal Tumor Center, Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.ORCID https://orcid.org/0000-0002-2441-3091
Shaohui HeSpinal Tumor Center, Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.ORCID https://orcid.org/0000-0003-3569-0059
Haiyi GongSpinal Tumor Center, Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.ORCID https://orcid.org/0000-0002-0600-1288
Yao WangSpinal Tumor Center, Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.ORCID https://orcid.org/0000-0002-2252-6287
Wei WeiSpinal Tumor Center, Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.ORCID https://orcid.org/0000-0002-7466-9239
Jun ChenDepartment of Pathology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.ORCID https://orcid.org/0000-0002-6608-2243
Jinbo HuSpinal Tumor Center, Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.ORCID https://orcid.org/0000-0002-5256-5287
Chen YeSpinal Tumor Center, Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.ORCID https://orcid.org/0000-0001-6853-3282
Shuchen LiuHuangSchool of Design and Innovation, China Academy of Art, Hangzhou, China.ORCID https://orcid.org/0000-0002-8123-0996
Saiying JinSchool of Design and Innovation, China Academy of Art, Hangzhou, China.ORCID https://orcid.org/0000-0001-9131-5232
Haifeng WeiSpinal Tumor Center, Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.ORCID https://orcid.org/0000-0001-5923-6155
Wei XuSpinal Tumor Center, Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.ORCID https://orcid.org/0000-0002-9931-8371
Jianru XiaoSpinal Tumor Center, Department of Orthopaedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.ORCID https://orcid.org/0000-0002-5828-7513
Second Military Medical University · CNChina Academy of Art · CNUniversity of Shanghai for Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ferroptosis has gained significant attention from oncologists as a vital outcome of oxidative stress. The aim of this study was to develop a prognostic signature that was based on the ferroptosis-related genes (FRGs) for osteosarcoma patients and explore their specific role in osteosarcoma. Methods: The training cohort dataset was extracted from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database. Different techniques like the univariate Cox regression, least absolute shrinkage and selection operator (LASSO) regression, multivariate Cox regression analyses, and the Kaplan-Meier (KM) survival analyses were utilized to develop a prognostic signature. Then, the intrinsic relationship between the developed gene signature and the infiltration levels of the immune cells was further investigated. An external validation dataset from the Gene Expression Omnibus (GEO) database was employed to assess the predictive ability of the developed gene signature. Subsequently, the specific function of potential FRG in affecting the oxidative stress reaction and ferroptosis of osteosarcoma cells was identified. Results: A prognostic signature based on 5 FRGs (CBS, MUC1, ATG7, SOCS1, and PEBP1) was developed, and the patients were classified into the low- and high-risk groups (categories). High-risk patients displayed poor overall survival outcomes. The risk level was seen to be an independent risk factor for determining the prognosis of osteosarcoma patients ( Conclusions: A novel FRG signature was developed in this study to predict the prognosis of osteosarcoma patients. The results indicated that ATG7 might regulate the process of oxidative stress and ferroptosis in osteosarcoma cells and could be used as a potential target to develop therapeutic strategies for treating osteosarcoma.

Indexed as

Autophagy-Related Protein 7Bone NeoplasmsFerroptosisOsteosarcomaGene Expression ProfilingHumansKaplan-Meier EstimateOxidative StressATG7 protein, humanAutophagy-Related Protein 7

Identifiers

PMID36254233
PMCPMC9569205
OpenAlexW4303832856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.